BKI 1708
BKI 1708 is a potent and orally active calcium-dependent protein kinase 1 (CDPK1) inhibitor (IC50 = 0.7 nM) . BKI 1708 exhibits potent activity against Neospora (IC50 = 481 nM) and Toxoplasma (IC50 = 122 nM) . BKI-1708 induces the formation of multinucleated complexes. BKI-1708 efficiently inhibits vertical transmission of both parasites and increases pup survival in mice[1][2].
Product Specifications
CAS Number
[2332840-70-5]
UNSPSC
12352005
Target
Parasite
Related Pathways
Anti-infection
Field of Research
Infection
Smiles
O=C(C1=C(N)N(CC(C)(CO)C)N=C1C2=CC3=C(C=C(C=C3)OC4CC4)C=C2)N
Molecular Formula
C22H26N4O3
Molecular Weight
394.47
References & Citations
[1]de Sousa MCF, et al. Efficacy of the bumped kinase inhibitor BKI-1708 against the cyst-forming apicomplexan parasites Toxoplasma gondii and Neospora caninum in vitro and in experimentally infected mice. Int J Parasitol Drugs Drug Resist. 2024 Aug;25:100553.|[2]Wenlin Huang, et al. Development of 5-Aminopyrazole-4-Carboxamide-Based Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. Journal of Medicinal Chemistry 2019, 62 (6), 3135-3146.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6212553-01 0.1 mL
MLX (Max-like Protein X, Max-like bHLHZip Protein, BigMax Protein, Transcription Factor-like Protein 4, Class D Basic Helix-loop-helix Protein 13, bHLHd13, TCFL4) (MaxLight 550)
Ask
View Details MBS6212553-02 5x 0.1 mL
MLX (Max-like Protein X, Max-like bHLHZip Protein, BigMax Protein, Transcription Factor-like Protein 4, Class D Basic Helix-loop-helix Protein 13, bHLHd13, TCFL4) (MaxLight 550)
Ask
View Details